Novel approaches to therapy for SLE

Authors: Zandman-Goddard, Gisele¹; Shoenfeld, Yehuda²

Source: Clinical Reviews in Allergy and Immunology, Volume 25, Number 1, July 2003 , pp. 105-111(7)

Buy & download fulltext article:

Price: $42.00 plus tax (Refund Policy)

Abstract:

Systemic lupus erythermatosus (SLE) is an autoimmune disease manifested by multi-organ involvement and elevated titers of anti-DNA antibodies. Current therapies for SLE are broadspectrum, and include steroids and immunosuppresive cytotoxic agents that are counterbalanced by the toxicity and side effects of the medications. One of the goals is to target thrapeies by altering specific known mechanisms of inflammation and autoimmunity. Although the inciting antigen is still unknown in SLE, it may be possible to alter the regulation of the immune response by targeted molecular therapy. Methods under investigation, which may be beneficial, are manipulation of second-signal stimulation of the immune response (anti-CD40L) manipulation of cytokines (monoclonal anti-IL-10), inducing tolerance by administration of blocking peptides (LJP394), and the manipulation of idiotypes (IVIg). In this article, we also discuss modalities that are steroid-sparing (MTX), and selective immunosuppression (stem-cell restoration and MMF). We review the ongoing literature from 2000-2002, utilizing the MEDLINE search. Controlled trials, open trials, and trials in phase I and II have been included, and anecdotal reports were excluded. The major advances have been with mycophenolate mofetil (MMF) and LJP 394

Keywords: SLE; DHEA; MMF; SCT; IVIG; LJP 394; IDEC-131; monoclonal anti-IL-10

Document Type: Research article

DOI: http://dx.doi.org/10.1385/CRIAI:25:1:105

Affiliations: 1: Center for Autoimmune Diseases, Department of Medicien B, Sheba Medical Center, Tel Hashomer, Israel, 2: Center for Autoimmune Diseases, Department of Medicien B, Sheba Medical Center, Tel Hashomer, Israel, Email: shoenfel@post.tau.ac.il

Publication date: 2003-07-01